MBRX vs TDG · $8.2M cap vs P/E 41, rev $8.83B
Moleculin Biotech Inc (MBRX) versus Transdigm Group Incorporated (TDG) — a side-by-side from cached financials, not a winner call.
Moleculin Biotech Inc (MBRX) is a biotechnology company listed on US.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
Latest reported MBRX revenue for 2026-06-30 was $0. Net income was -$20.5M. MBRX currently screens at market cap $8.2M.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
MBRX currently screens at market cap $8.2M. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Not investment advice. Open the MBRX and TDG stock pages for the full models.
Not investment advice.